Technology Introduction Contract Signed for INV-008 (15-PGDH Inhibitor)
- Signed exclusive worldwide license and co-development contract for INV-008, a 15-PGDH inhibitor targeting IBD (Inflammatory Bowel Disease) and additional indications
- Counterparty: Innovo Therapeutics (South Korea); Contract date: May 12, 2026
- Term: 15 years from first commercial sale or until last expiring Background IP, whichever is later
- Total contract value up to KRW 662.5 billion (based on IBD indication, excluding additional indication royalties)
- Upfront payment of KRW 6.5 billion (non-refundable), development milestones up to KRW 19 billion, regulatory milestones up to KRW 207 billion, sales milestones up to KRW 430 billion, plus separate royalties
- Conditional contract: may be terminated if clinical trials or regulatory approvals fail; clinical supply cost settlement up to KRW 1 billion excluded
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: Major Management Matters Related to Investment Decision (INV008(15PGDH Inhibitor) Technology Introduction Contract Execution)
- Company: Daewoong Pharma (069620)
- Submission: Daewoong Pharma
- Receipt: 05-12-2026
- Under KRX KOSPI Market Division